ASCO 2024: New data demonstrate benefits of Kimmtrak in mUM

Researchers from UK-based biotech Immunocore Holdings (Nasdaq: IMCR) shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction.

Immunocore’s US traded shares closed up 4.9% at $48.98 following the announcement.

The data from the Phase II trial found that mUM patients with stable disease and a ‘partial response’ have similar clinical outcomes to patients with partial responses. The company explained that partial response is defined as confirmed tumor reduction of greater than 10%, but less than 30%. To be considered a partial response, the measurable size of the tumor has to be reduced by at least 30% to 50% due to the treatment.